ArticleAntimicrobial agents and chemotherapy2011
Activity of and development of resistance to corallopyronin A, an inhibitor of RNA polymerase.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Constrained RNA polymerase mutational pathways distinguish corallopyronin A resistance from rifampicin resistance in staphylococci.Scientific reports · 2026Article
- Activity of Corallopyronin A Against ESKAPEE Pathogens: Potential and Translational Implications.Antibiotics (Basel, Switzerland) · 2026Article
- A laboratory-based predictive pathway for the development ofMicrobiology spectrum · 2024Article
- Addressing Sexually Transmitted Infections Due toMicroorganisms · 2024Review
- Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-ResistantPharmaceutics · 2022Article
- PotentmSphere · 2022Article
- The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin inAntibiotics (Basel, Switzerland) · 2022Article
- Elaborations on Corallopyronin A as a Novel Treatment Strategy Against Genital Chlamydial Infections.Frontiers in microbiology · 2019Article
- Structural basis of head to head polyketide fusion by CorB.Chemical science · 2015Article
- Frequency, spectrum, and nonzero fitness costs of resistance to myxopyronin in Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2012Article
- Novel rapidly diversifiable antimicrobial RNA polymerase switch region inhibitors with confirmed mode of action in Haemophilus influenzae.Journal of bacteriology · 2012Article
- Influence of DNA template choice on transcription and inhibition of Escherichia coli RNA polymerase.Antimicrobial agents and chemotherapy · 2012Article
- New target for inhibition of bacterial RNA polymerase: 'switch region'.Current opinion in microbiology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
We explored the properties of corallopyronin A (CorA), a poorly characterized inhibitor of bacterial RNA polymerase (RNAP). It displayed a 50% inhibitory concentration of 0.73 μM against RNAP, compared with 11.5 nM for rifampin. The antibacterial activity of CorA was also inferior to rifampin, and resistant mutants of Staphylococcus aureus were easily selected. The mutations conferring resistance resided in the rpoB and rpoC subunits of RNAP. We conclude that CorA is not a promising antibacterial drug candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.